EGFR and breast cancer: More than ten years later, Feng and colleagues discovered that breast cancer cells could escape lapatinib (an oral dual tyrosine kinase inhibitor that targets epidermal growth factor receptor-EGFR and HER2) and consequently survive by displaying a change toward CD36-mediated FA uptake 61,69.